Evidence map›Paper›PMID 39816532›Full record

ArticleHemaSphere2025

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

Christine E Ryan, Yue Ren, Svitlana Tyekucheva, Jon E Arnason, Adam M Boruchov, Caron A Jacobson, David C Fisher, Hari Miskin, Peter Sportelli, Jennifer R Brown and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christine E RyanDepartment of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.ORCID 0000-0003-2588-1943
Yue RenDepartment of Data Science Dana-Farber Cancer Institute Boston Massachusetts USA.
Svitlana TyekuchevaDepartment of Data Science Dana-Farber Cancer Institute Boston Massachusetts USA.
Jon E ArnasonDepartment of Medical Oncology Beth Israel Deaconess Medical Center Boston Massachusetts USA.
Adam M BoruchovCancer Institute, Nuvance Health Danbury Connecticut USA.
Caron A JacobsonDepartment of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.
David C FisherDepartment of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.
Hari MiskinTG Therapeutics New York USA.
Peter SportelliTG Therapeutics New York USA.
Jennifer R BrownDepartment of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.ORCID 0000-0003-2040-4961
Matthew S DavidsDepartment of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.ORCID https://orcid.org/0000-0003-4529-2003

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0M
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemiaR01CA266298 · NCI · DANA-FARBER CANCER INST · PI MATTHEW S DAVIDS · 2022 to 2026
$2.0M
NCI NIH HHS P01 CA206978NCI NIH HHS R01 CA266298NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39816532
PMCPMC11733307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.